Patents Assigned to Oregon Health & Science University
  • Methods and compositions used in treating inflammatory and autoimmune diseases
    Patent number: 10137177
    Abstract: Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation. The pharmaceutical compositions and pharmacological dose comprise a safe and effective amount of WE thrombin.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: November 27, 2018
    Assignees: Oregon Health & Science University, The United States of America as respresented by the Department of Veterans Affairs
    Inventors: Owen J. McCarty, Norah Verbout, Halina Offner-Vandenbark, Erik I. Tucker
  • Human leucine zipper/trail recombinant polypeptides
    Patent number: 10131701
    Abstract: Disclosed are recombinant polypeptides that include human TRAIL sequences as well as human leucine zipper motifs as well as polynucleotides that encode the recombinant polypeptides, expression vectors that comprise the polynucleotides, pharmaceutical compositions comprising the polypeptides, and methods of using the pharmaceutical compositions for the treatment of cancer. Further disclosed are TRAIL sequences with stabilizing mutations and methods of expressing the disclosed polypeptides in E. coli.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 20, 2018
    Assignees: Oregon Health & Science University, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Dmitri Rozanov, Alexander Aleshin
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20180327854
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 15, 2018
    Applicants: Celator Pharmaceuticals Inc., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Systems and methods for retinal layer segmentation in OCT imaging and OCT angiography
    Patent number: 10123689
    Abstract: Disclosed herein are methods and systems for segmenting, visualizing, and quantifying the layered structure of retina in optical coherence tomography datasets. The disclosed methods have particular application to OCT angiography data, where specific retina layers have distinct vascular structures and characteristics that can be altered in various pathological conditions of the eye.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: November 13, 2018
    Assignee: Oregon Health & Science University
    Inventors: Yali Jia, David Huang, Miao Zhang
  • CMV glycoproteins and recombinant vectors
    Patent number: 10101329
    Abstract: This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 16, 2018
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Klaus Frueh, Scott G. Hansen, Colin Powers
  • Methods of detecting cancers sensitive to cabozantinib
    Patent number: 10100366
    Abstract: The emergence of resistance to targeted therapy is a recurrent clinical challenge and requires development and validation of secondary agents with improved activity. Accompanied by experimental cell-based and structural validation, this report of a near complete response to cabozantinib in a ROS1-rearranged lung adenocarcinoma patient with acquired resistance to crizotinib mediated by a novel CD74-ROS1 D2033N solvent-front mutation provides the first clinical example of crizotinib resistance overcome by targeted therapy in a ROS1-rearranged malignancy.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: October 16, 2018
    Assignee: Oregon Health & Science University
    Inventor: Monika A. Davare
  • DRALPHA1-MOG-35-55 TREATMENT OF TRAUMATIC BRAIN INJURY
    Publication number: 20180271935
    Abstract: Methods and compositions used in treating traumatic brain injury using a recombinant DR?-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DR?-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had a traumatic brain injury.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Halina Offner, Arthur Vandenbark
  • SMALL MOLECULES THAT BIND MR1
    Publication number: 20180273536
    Abstract: Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 27, 2018
    Applicants: OREGON HEALTH & SCIENCE UNIVERSITY, HE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: David Lewinsohn, Melanie Harriff, Aaron Nilsen, Haihong Jin, Erin Adams, Cara Froyd, Curtis McMurtrey, William Hildebrand
  • DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES
    Publication number: 20180271972
    Abstract: Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 27, 2018
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn ROSS, Terianne Maiko WONG, Donald Martin CARTER, Jr.
  • Cellular activity quantification using labeled probes
    Patent number: 10083341
    Abstract: Methods and systems for quantifying cellular activity using labeled probes, e.g., quantum dots, are disclosed. In one example approach, a method for quantifying cellular activity in a sample containing intact cells having labeled complexes comprises receiving images of the sample at a plurality of depths and detecting individual intact cells in the images of the sample at the plurality of depths. For each detected cell, discrete labels may be detected and localized in the cell at each depth, a total number of detected and localized labels may be calculated in the cell, and an activity level of the target molecule for the labeled probe in the cell determined.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 25, 2018
    Assignee: Oregon Health & Science University
    Inventors: Tania Vu, Thomas Jacob
  • Method and apparatus for noninvasive quantitative detection of fibrosis in normal and viable myocardium by MRI
    Patent number: 10076246
    Abstract: Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 18, 2018
    Assignee: Oregon Health & Science University
    Inventors: Michael Jerosch-Herold, Sumeet S. Chugh
  • Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and LC/MS/MS workflow
    Patent number: 10078091
    Abstract: A method, a labeling reagent, sets of labeling reagents, and labeling techniques are provided for the analysis of ketosterol biomarkers such as bile acid precursors from human plasma, serum or whole blood. This method is used for new born screening for Cerebrotendinous Xanthomatosis (CTX). Methods for labeling, analyzing, and quantifying ketosterol biomarkers are also disclosed as are methods that also use mass spectrometry.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 18, 2018
    Assignees: DH Technologies Development Pte. Ltd., Oregon Health and Science University
    Inventors: Andrea DeBarber, Subhasish Purkayastha, Robert D. Steiner, Michal Weinstock
  • Dental composites
    Patent number: 10071027
    Abstract: Disclosed herein are methacrylate compounds that can be used as components of dental composites. Also disclosed are dental composites comprising the compositions and thiourethane oligomers.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: September 11, 2018
    Assignee: Oregon Health & Science University
    Inventors: Carmem S. Pfeifer, Jack L. Ferracane
  • OCT vitrectomy probe
    Patent number: 10070784
    Abstract: Disclosed herein are vitrectomy probes configured for use with optical coherence tomography.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: September 11, 2018
    Assignee: Oregon Health & Science University
    Inventors: David Huang, Yimin Wang, David Wilson, J. Timothy Stout, James Fujimoto, Chen Lu
  • SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA
    Publication number: 20180245165
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Arizona Regents on Behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Compounds, compositions and associated methods comprising 3-aryl quinolines
    Patent number: 10023538
    Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: July 17, 2018
    Assignees: The United States of America as represented by the Department of Veterans Affairs, Oregon Health and Science University
    Inventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
  • Rapid confocal microscopy to support surgical procedures
    Patent number: 10001635
    Abstract: One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second ranges A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of a nucleus dye. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 19, 2018
    Assignees: Sloan Kettering Institute for Cancer Research, Oregon Health and Science University
    Inventor: Daniel S. Gareau
  • Synthetic olgononucleotides for detection of nucleic acid binding proteins
    Patent number: 9989528
    Abstract: Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 5, 2018
    Assignee: Oregon Health & Science University
    Inventors: William Mathers, Zheng Ye
  • Recombinant HCMV and RHCMV vectors and uses thereof
    Patent number: 9982241
    Abstract: The recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors of this invention encode heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 29, 2018
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
  • Systems and methods of choroidal neovascularization detection using optical coherence tomography angiography
    Patent number: 9984464
    Abstract: Disclosed are systems and methods to automatically detect choroidal neovascularization (CNV) in the outer retina using OCT angiography. Further disclosed are methods of removing projection artifacts from the outer retina and for combining brightness, orientation, and position information in a context-aware saliency model to quantify CNV area in OCT angiograms.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 29, 2018
    Assignee: Oregon Health & Science University
    Inventors: Yali Jia, David Huang, Li Liu